A Phase I/II Study of TPI 287 - Temozolomide Combination in Melanoma

2014-08-27 03:16:00 | BioPortfolio


Phase I portion of study To determine the Maximum Tolerated Dose (MTD), as measured by clinical and laboratory adverse events, for the administration of TPI 287 administered weekly for three weeks out of every four, and then combined with temozolomide (Temodar) in patients with metastatic melanoma.

Phase II portion of study

1. Primary objective: To estimate the efficacy of TPI 287 - temozolomide combination as measured by percent of patients without tumor progression at 6 months,

2. Secondary objectives:

1. To evaluate the response rate, response duration, median progression-free survival (PFS), overall survival of patients with metastatic melanoma treated with TPI 287 - temozolomide combination.

2. To determine the long-term toxicity of TPI 287, administered intravenously on days 1, 8 and 15 (+/- 1 day) every four weeks plus temozolomide, given orally, once a day for five days every cycle (Days 1 through 5 [+1 day]) for the treatment of patients with metastatic melanoma.


Study Drugs:

TPI 287 is designed to block tumors from growing by preventing cancer cells from dividing.

Temozolomide is designed to kill cancer cells by causing breaks in the DNA (genetic material) of the cell.

Screening Tests:

You will have "screening tests" to help the doctor decide if you are eligible to take part in this study. The following tests and procedures will be performed on within 2 weeks before the first dose of study drugs (if eligible).

- Your complete medical history will be recorded.

- You will have a complete physical exam, including measurements of height, weight, and vital signs (temperature, heart rate, breathing rate, and blood pressure).

- You will be asked how well you are able to perform the normal activities of daily living (performance status).

- Blood (about 2 teaspoons) will be collected for routine blood tests. You may also be tested for HIV.

- You will have a chest X-ray to check the status of the disease.

- You will have a computed tomography (CT) scan of chest, abdomen, and pelvis to check the status of the disease.

- You will have an magnetic resonance imaging (MRI) scan of the brain to check on the status of the disease.

- You will be asked about any symptoms you may be experiencing and any drugs you may be taking.

- Women who are able to have children must have a negative blood (about 1 teaspoon) or urine pregnancy test.

The study doctor will discuss the screening test results with you. If the screening tests show that you are not eligible to take part in the study, you will not be enrolled. Other treatment options will be discussed with you.

Study Groups:

If you are found to be eligible to take part in this study, you will be assigned to a study group based on when you joined this study. Up to 8 groups of 6 participants will be enrolled in the Phase I portion of the study, and up to 64 participants will be enrolled in Phase II.

If you are enrolled in the Phase I portion, the dose of TPI 287 and temozolomide you receive will depend on when you joined this study. The first group of participants will receive the lowest dose level of TPI 287 and temozolomide. Each new group will receive a higher dose of TPI 287 and temozolomide than the group before it, if no intolerable side effects were seen. If any of these participants have a dose limiting toxicity, 6 additional participants will be added at the same dose. If a dose limiting toxicity occurs again, the dose level below this will be considered the maximum tolerated dose.

If any participant experiences a life threatening side effect, no additional participants will be enrolled into that dose level and no higher doses will be given. An additional 3 participants will be treated at the dose level below the one with life threatening toxicity. Once the maximum tolerated dose of the combination is found, Phase II of the study will open.

If you are enrolled in the Phase II portion, you will receive the drug combination at the highest dose that was tolerated in the Phase I portion

Central Venous Catheter (CVC):

You will have a CVC placed. A CVC is a sterile, flexible tube that will be placed into a large vein while you are under local anesthesia. Your doctor will explain this procedure to you in more detail, and you will be required to sign a separate consent form for this procedure.

Study Drug Administration:

You will receive TPI 287 by vein over 1 hour on Days 1, 8, and 15 (+/- 1 day) of each 28 day study cycle. Before you receive each dose of TPI 287, you will receive dexamethasone, Benadryl (diphenhydramine), and Pepcid (famotidine) by vein to help prevent allergic reaction. You will also receive drugs to prevent nausea and vomiting. Your vital signs will be measured before and 30 minutes following the end of the infusion of TPI 287. Your vitals will be measured more often, if needed.

You will take temozolomide tablets by mouth on Days 1-5 at bedtime. You should not eat for at least 1 hour before and 1 hour after taking temozolomide.

Study Visits:

Before each cycle, your performance status will be recorded and you will have a physical exam.

On Days 1, 8, and 14 of each cycle:

- Blood (about 1 teaspoon) will be drawn for routine tests before you receive TPI 287.

- You will also be asked about any symptoms you may be experiencing and any drugs you are taking.

On Day 22 of each cycle:

- Blood (about 1 teaspoon) will be drawn for routine tests.

- You will also be asked about any symptoms you may be experiencing and any drugs you are taking.

Every 8 weeks, you will have a CT scan or MRI scan to check the status of the disease. If you have brain metastasis, you will have the scans every 4 weeks.

Length of Study:

You will continue taking the study drugs for as long as you are benefitting. You will be taken off study if the disease gets worse or intolerable side effects occur.

End-of-Treatment Visit:

About 4 weeks after you stop taking TPI 287 in combination with Temozolomide, you have an end-of-study visit. At this visit, the following tests and procedures will be performed:

- You will have a physical exam.

- You will be asked about any complications or side effects you may be experiencing.

- Blood (about 2 tablespoons) will be drawn for routine tests.

- If your doctor thinks it is needed, you will have a CT scan or MRI scan to check the status of the disease.

Additional Information:

- You must follow all instructions and directions you are given while on study.

- You must check with your doctor first if you need to take any new over-the-counter drugs or herbal supplements, or if you need to change your usual prescription drugs during this study.

- You should not have any immunizations (vaccinations) without telling your doctor first.

- You should not donate blood while on study or for 70 days after your last dose of the study drug.

- You must tell your doctor about any medical treatments that you will have to get during the study (such as elective surgery).

Certain drugs cannot be taken while you are in this study. Your doctor will explain what these medications are. If you need treatment with any medications that are not allowed during this study, you must tell your doctor or the study staff. You will not be denied medications required to treat an illness you may have, but you may be required to stop taking the study drugs.

This is an investigational study. TPI 287 is not FDA approved or commercially available. At this time, TPI 287 is being used in research only. Temozolomide is FDA approved and commercially available for primary brain cancer. The use of temozolomide in combination with TPI 287 is investigational.

Up to 106 patients will take part in this study. All patients will be enrolled at M. D. Anderson.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment




TPI 287, Temodar (Temozolomide)


UT MD Anderson Cancer Center
United States




M.D. Anderson Cancer Center

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:16:00-0400

Clinical Trials [1344 Associated Clinical Trials listed on BioPortfolio]

Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma

A single arm Phase 2 trial with the study drug temozolomide (temodar) for newly diagnosed glioblastoma in elderly patients (defined as greater than or equal to 70 years old). Following sur...

Biochemotherapy With Temozolomide for Metastatic Melanoma

The goal of this clinical research study is to learn if treatment with Temodar (temozolomide), Velban (vinblastine), Cisplatin, Proleukin (interleukin-2), Intron-A (interferon alpha), and ...

Taxotere/Temodar/Cisplatin Study in Melanoma Patients

Primary Objective: 1. To determine the maximum tolerated dose of chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic melanoma. Secondary Objectives: ...

Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas

Objectives: To determine maximum tolerated dose of CPT-11 when administered following Temodar plus O6-benzylguanine To characterize any toxicity associated w combo of CPT-11 + Temodar pl...

Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients

The goal of this clinical research study is to find the highest safe dose of lomustine (CCNU, CeeNU) that can be given with temozolomide (Temodar) and thalidomide (Thalomid) in the treatme...

PubMed Articles [948 Associated PubMed Articles listed on BioPortfolio]

Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure.

Asian melanoma patients, predominantly comprised of acral and mucosal subtypes, might not benefit from immunotherapy and targeted therapy as much as Caucasian patients. Novel treatment strategies are ...

Phase 2 Study of Radiation Therapy Plus Low Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420.

Evaluate the toxicity and efficacy of adjuvant temozolomide (TMZ) and irinotecan (CPT-11) for 12 months following concurrent chemo-radiation in newly diagnosed glioblastoma (GBM).

Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma.

In this phase II study, we investigate clinical outcomes and tolerability of hypofractionated radiotherapy (HRT) combined with temozolomide (TMZ) to treat elderly patients with glioblastoma (GBM).

Variation in daily ultraviolet light exposure and sun protection behaviours of melanoma survivors: an observational single-arm pilot study with a wearable sensor.

Melanoma survivors are at risk to develop another melanoma and the same patterns of sun exposure that caused the initial melanoma contribute to the risk for a second melanoma. Despite awareness of the...

Impact of primary care provider density on detection and diagnosis of cutaneous melanoma.

Early diagnosis of cutaneous melanoma is critical in preventing melanoma-associated deaths, but the role of primary care providers (PCPs) in diagnosing melanoma is underexplored. We aimed to explore t...

Medical and Biotech [MESH] Definitions

An unpigmented malignant melanoma. It is an anaplastic melanoma consisting of cells derived from melanoblasts but not forming melanin. (Dorland, 27th ed; Stedman, 25th ed)

Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.

A cellular subtype of malignant melanoma. It is a pigmented lesion composed of melanocytes occurring on sun-exposed skin, usually the face and neck. The melanocytes are commonly multinucleated with a "starburst" appearance. It is considered by many to be the in situ phase of lentigo maligna melanoma.

Found in large amounts in the plasma and urine of patients with malignant melanoma. It is therefore used in the diagnosis of melanoma and for the detection of postoperative metastases. Cysteinyldopa is believed to be formed by the rapid enzymatic hydrolysis of 5-S-glutathionedopa found in melanin-producing cells.

A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.

More From BioPortfolio on "A Phase I/II Study of TPI 287 - Temozolomide Combination in Melanoma"

Quick Search


Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Melanoma is a highly malignant tumor of melanin-forming cells (melanocytes) There are most commonly found in the skin (resulting from sunlight exposure), but also in the eyes and mucous membranes. Metastasis to other regions of the body is also common....

Searches Linking to this Trial